IP Library Assignment 017636/0360
Patent Assignment
Reel/Frame 017636/0360

Change of Name

Recorded: 2006-05-18 Pages: 5
Assignor
Assignee
AVENTIS PHARMACEUTICALS INC.
300 SOMERSET CORPORATE BLVD., BRIDGEWATER, NEW JERSEY, 08807-2854
Covered Properties (37)
Quinoline Derivatives and Use Thereof as Antagonists of Leukotriene D4
Patent: 4,920,132 →
Application: 07/116,420 →
Quinoline Derivatives and Use Thereof as Antagonists of Leukotriene D4
Patent: 4,920,133 →
Application: 07/116,428 →
Quinoline Derivatives and Use Thereof as Antagonists of Leukotriene D4
Patent: 4,920,130 →
Application: 07/116,597 →
Quinolinyl Ether or Thioether Tetrazoles as Agents for the Treatment of Hypersensitive Ailments
Patent: 4,874,769 →
Application: 07/124,800 →
Method for the Preparation of a Theophylline Sustained Release Pharmaceutical Composition and the Composition Prepared Thereby
Patent: 5,026,709 →
Application: 07/203,435 →
Product-Dispensing Method and Apparatus
Patent: 4,876,891 →
Application: 07/203,566 →
Quinoline Derivatives and Use Thereof as Antagonists of Leukotriene D4
Patent: 4,920,131 →
Application: 07/209,428 →
Intranasal Calcitonin Formulations
Patent: 5,026,825 →
Application: 07/242,000 →
Quinoline Derivatives and Their Use as Antagonists of Leukotriene D4
Patent: 5,059,610 →
Application: 07/477,896 →
Quinoline Derivatives as Antagonists of Leukotriene D4
Patent: 5,028,615 →
Application: 07/499,513 →
Binding Theophylline to Ion Exchange Resins
Patent: 5,162,110 →
Application: 07/629,833 →
Product-Dispensing Method and Apparatus
Patent: 5,125,466 →
Application: 07/649,304 →
Quinoline Derivatives as Antagonists of Leukotriene D4
Patent: 5,166,210 →
Application: 07/724,745 →
Pluripotential Quiescent Stem Cell Population
Patent: 5,807,686 →
Application: 08/482,318 →
Bis Mono-and Bicyclic Aryl and Heteroaryl Compounds Which Inhibit Egf and/or Pdgf Receptor Tyrosine Kinase
Patent: 6,057,320 →
Application: 08/881,991 →
Process for the Solid Phase Synthesis of Aldehyde Ketone Oxime Amine Hydroxamic Acid and a -B-Unsaturated Carboxylic Acid and Aldehyde Compounds
Patent: 6,133,409 →
Application: 09/103,872 →
Process for Preparing 2,4- Dihydroxypyridine and 2,4- Dihydroxy-3-Nitropyridine
Patent: 6,307,054 →
Application: 09/108,622 →
Pharmaceutical Composition Comprising a Compound Having Anti-Xa Activity and a Platelet Aggregation Antagonist Compound
Patent: 6,103,705 →
Application: 09/192,710 →
Quinoline and Quinoxaline Compounds Which Inhibit Platelet-Derived Growth Factor and/or P56LCK Tyrosine Kinases
Patent: 6,180,632 →
Application: 09/198,718 →
Quinoline and Quinoxaline Compounds Which Inhibit Platelet-Derived Growth Factor and/or P56LCK Tyrosine Kinases
Patent: 6,245,760 →
Application: 09/198,720 →
Piperididinyl and N-Amidinopiperidinyl Derivatives
Patent: 6,277,865 →
Application: 09/273,618 →
Functionalized Resin for the Synthesis of Amides and Peptides
Patent: 6,127,515 →
Application: 09/316,671 →
Elastomer Treatment Process to Decrease Peroxide Levels
Patent: 6,248,841 →
Application: 09/355,693 →
Substituted Beta-Thiocarboxylic Acids
Patent: 6,306,873 →
Application: 09/357,734 →
Luciferase Reporter Bioassay of Parathyroid Hormone Compounds
Patent: 6,720,153 →
Application: 09/387,176 →
Process for the Solid Phase Synthesis of Aldehyde, Ketone, Oxime, Amine, Hydroxamic Acid and a,B-Unsaturated Carboxylic Acid and Aldehyde Compounds
Patent: 6,392,010 →
Application: 09/469,829 →
Process For Preparing N6-Substituted Adenosine Derivatives
Patent: 6,184,382 →
Application: 09/481,979 →
Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides
Patent: 6,180,759 →
Application: 09/544,680 →
Aqueous-based pharmaceutical composition
Patent: 6,375,984 →
Application: 09/561,371 →
Nuclear Factor Kappab Inducing Factor
Patent: 7,041,497 →
Application: 09/823,119 →
Publication: US 2003/0170862
Variants of TRAF2 Which Act as an Inhibitor of Tnf-Alpha (Tnfalpha) Signaling Pathway
Patent: 6,998,475 →
Application: 10/018,030 →
Llg Polypeptides of the Triacylglycerol Lipase Family, and Compositions and Methods for Their Use in Enzymatic Hydrolysis, and Protein and Gene Therapies
Patent: 7,056,720 →
Application: 10/128,449 →
Publication: US 2003/0108538
Quinoline and Quinoxaline Compounds Which Inhibit Platelet-Derived Growth Factor and/or P56LCK Tyrosine Kinases
Patent: 6,852,712 →
Application: 10/357,882 →
Publication: US 2003/0139399
Osteopontin, oligodendrocytes and myelination
Application: 10/602,927 →
Publication: US 2004/0033226
Substituted Oxoazaheterocyclyl Compounds
Patent: 7,612,075 →
Application: 10/628,093 →
Publication: US 2004/0102450
Variants of TRAF2 Which Act as an Inhibitor of Tnf-Alpha (Tnfalpha) Signaling Pathway
Patent: 7,332,593 →
Application: 11/294,246 →
Publication: US 2007/0015699
Nuclear Factor Kappab Inducing Factor
Patent: 7,972,844 →
Application: 11/354,560 →
Publication: US 2006/0223771
Related Assignments (4)
Other recorded transfers of the patents in this record — the chain of ownership.
Change of Name Oct 4, 2001
From: RHONE-POULENC RORER PHARMACEUTICALS INC.
To: AVENTIS PHARMACEUTICALS PRODUCTS INC.
Reel/Frame 012036/0167 →
Change of Name Oct 8, 2001
From: RORER PHARMACEUTICAL CORPORATION
To: RHONE-POULENC RORER PHARMACEUTICALS INC.
Reel/Frame 012036/0745 →
Certificate of Conversion Dec 9, 2014
From: AVENTISUB INC.
To: AVENTISUB LLC
Reel/Frame 034566/0976 →
Merger Jan 19, 2015
From: AVENTIS PHARMACEUTICALS INC.
To: AVENTISUB LLC
Reel/Frame 034781/0334 →